why choose us

First received: April 25, 2023

Clinical Trial: Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

Study Status: Completed

Recruit Status: RECRUITING

Condition: Systemic Lupus Erythematosus

Study Type: INTERVENTIONAL


Official Title: SELECT-SLE: A Phase 3 Program to Evaluate the Safety and Efficacy of Upadacitinib in Subjects With Moderately to Severely Active SLE

Brief Summary: Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems.This study will assess how safe and effective upadacitinib is in treating adult participants with moderately to severely active SLE.Adverse events and change in the disease activity will be assessed.Upadacitinib is an approved drug for rheumatoid arthritis, psoriatic arthritis, and axial spondylarthritis and is being developed for the treatment of SLE.This study is "double-blinded",…

Read more